<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) is a provisional category of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> which is morphologically intermediate between Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LBCL) </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical significance of this <z:mp ids='MP_0000002'>morphology</z:mp> is controversial </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We examined 41 cases of pediatric B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by immunohistochemistry for proteins associated with proto-oncogenes c-myc, BCL-2 and BCL-6 and a subset of cases (with adequate slides) for a proliferation-associated marker (Ki-67) and for <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (Apop-Tag) </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>, thirteen cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and twelve cases of LBCL were examined </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Our results showed BCL-6 expression in 16 of 16 BLL, 4 of 13 BL, and 9 of 12 LBCL; c-myc expression in 14 of 15 BLL, 9 of 13 BL, and 12 of 12 LBCL; and BCL-2 expression in 2 of 16 BLL, 9 of 13 BL, and 6 of 12 LBCL </plain></SENT>
<SENT sid="5" pm="."><plain>Mean apoptotic index for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> was 10.3% (n = 6); for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> was 17.1% (n = 5); and for LBCL was 10.9% (n = 6) </plain></SENT>
<SENT sid="6" pm="."><plain>Ki-67 was diffusely reactive in <z:hpo ids='HP_0000001'>all</z:hpo> cases tested </plain></SENT>
<SENT sid="7" pm="."><plain>There was a significantly higher proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> which expressed BCL-6 (P = 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Labeling for BCL-6 distinguishes <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It is likely that in children in North America, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> is biologically distinct from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and more closely resembles a subset of LBCL </plain></SENT>
</text></document>